Menu
GASTROClear
FAQs and Datasheet

GASTROClear

Gastric Cancer is Curable
if Detected Early

GASTROClear is a cancer blood test, the first of its kind in the world. Designed to detect gastric cancer in people who may not yet be experiencing any symptoms.

GASTROClear

Blood Test for Early Detection of Gastric Cancer

Clinical Studies

Gastric cancer is the 5th leading cause of cancer deaths worldwide

More than 60% of gastric cancer patients are diagnosed in the later stages.

Over 1 million people worldwide are diagnosed with gastric cancer and over 800,000 people die of the disease.

Survival rate drops to less than 20% for a patient diagnosed with stage-4 gastric cancer.

First
Second
Third
Early detection improves gastric cancer survival

Countries with high incidence rates of gastric cancer, like Japan and South Korea, have implemented national screening programs to enable earlier diagnosis, achieving excellent results with more than 50% diagnosis at early stages.

Without a gastric-cancer-screening program, individuals tend to only seek medical attention when they are symptomatic and often when these symptoms are severe, by which time the cancer is usually in its advanced stages.

What is the science and evidence behind GASTROClear?

GASTROClear measures microRNAs, the smallest strands of genetic material that bind to and degrade RNA transcripts of protein-coding genes. These molecules help to regulate the function of genes, which makes them important to regular biological processes of cells in the body. Abnormal levels of microRNA are associated with cancer and other diseases, forming a disease signature that can be an important biomarker for detecting problems when they are less serious and more treatable.

GASTROClear uses a PCR-based technology, patented by Mirxes, together with a clinically-validated algorithm to detect a unique signature of 12 microRNAs that have been associated with gastric cancer. The assay was developed and validated through large-scale clinical studies in Singapore and Korea involving over 5,000 people. The assay achieved a sensitivity of 81–82% and specificity of 88–90% in case-control cohort studies, and a sensitivity of 87% and specificity of 68% in a prospective validation cohort comprising high-risk, symptomatic patients who were indicated for gastroscopy.

Direct comparison with other blood-based biomarkers, such as Helicobacter pylori serology, serum pepsinogen, and other tumor markers, showed that GASTROClear was at least 20% more accurate in detecting gastric cancer.

View Document
Watch Video
How can GASTROClear help patients?

GASTROClear detects cancer-associated microRNA biomarker signatures that are present in a person’s blood before symptoms appear.

It is a minimally-invasive blood test that detects all stages of gastric cancer (stages 1–4) with close to 90% sensitivity.

The GASTROClear test gives a risk score together with actionable recommendations for physicians to manage patients who are assessed to be at high, moderate, and low risk of gastric cancer.

Do you want to learn more about gastric cancer?
Early detection of gastric cancer

Regular screening can increase the chances of detecting gastric cancer in the early stages. Find out how you can prevent and detect gastric cancer early.

Learn More
Symptoms of gastric cancer

Gastric cancer usually shows no signs or symptoms in the early stages. Knowing and proactively managing your risk through regular screening is the key to early detection.

Learn More
Gastric cancer treatment

Early diagnosis coupled with timely life-saving treatment can lead to good outcomes for patients with gastric cancer.

Learn More
Frequently Asked Questions

Gastric cancer is a disease in which malignant, or cancerous, cells form in the lining of the stomach.

The first signs of gastric cancer are often vague. Specifically, the signs may be heartburn, indigestion, a change in appetite, nausea, and vomiting.

Men are at higher risk of gastric cancer than women. However, the signs and symptoms of gastric cancer are similar for men and women.

Gastric cancer typically causes no symptoms in the early stages of the disease. As the disease advances, the symptoms are often vague and non-specific.

There is no sure way to prevent gastric cancer, but there are things you can do to lower your risk. These include staying at a healthy weight, maintaining a lifestyle with regular physical activity, avoiding or limiting alcohol, and keeping to a healthy diet.

Stomach cancer is curable if detected in the early stages.

Gastroscopy, also known as upper gastrointestinal endoscopy or oesophago-gastro-duodenoscopy (OGD), is a procedure where a tube with a light and camera on it is used to look for any physical changes on the surface of the upper digestive tract.

You are required to fast for at least 6 hours before the procedure to ensure that your stomach is completely empty.

No special preparation is needed for the GASTROClear test, which only requires a simple blood draw.

No. Other tests can suggest that cancer is present, but a confirmed diagnosis is only possible with a biopsy.

Hereditary diffuse gastric cancer (HDGC) is a rare inherited condition associated with an increased risk of gastric cancer. The gene most commonly associated with HDGC is called CDH1. A mutation (alteration) in the CDH1 gene gives a person an increased risk of developing gastric cancer.

Where can you get tested?

The GASTROClear test is available at over 200 clinics and hospitals in Singapore.

View Locations

Investor Relations
Investor Relations